

EMA/470009/2023

European Medicines Agency decision P/0445/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein, recombinant *Neisseria meningitidis* serogroup B protein 1, recombinant *Neisseria meningitidis* serogroup B protein 2, recombinant *Neisseria meningitidis* serogroup B protein 3, *Neisseria meningitidis* serogroup B protein-based active substance (MenPenta vaccine), (EMEA-003379-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0445/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein, recombinant *Neisseria meningitidis* serogroup B protein 1, recombinant *Neisseria meningitidis* serogroup B protein 2, recombinant *Neisseria meningitidis* serogroup B protein 3, *Neisseria meningitidis* serogroup B protein-based active substance (MenPenta vaccine), (EMEA-003379-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Sanofi Pasteur on 16 December 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 September 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein, recombinant *Neisseria meningitidis* serogroup B protein 1, recombinant *Neisseria meningitidis* serogroup B protein 2, recombinant *Neisseria meningitidis* serogroup B protein 3, *Neisseria meningitidis* serogroup B protein-based active substance (MenPenta vaccine), suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein, recombinant *Neisseria meningitidis* serogroup B protein 1, recombinant *Neisseria meningitidis* serogroup B protein 2, recombinant *Neisseria meningitidis* serogroup B protein 3, *Neisseria meningitidis* serogroup B protein-based active substance (MenPenta vaccine), suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein, recombinant *Neisseria meningitidis* serogroup B protein 1, recombinant *Neisseria meningitidis* serogroup B protein 2, recombinant *Neisseria meningitidis* serogroup B protein 3, *Neisseria meningitidis* serogroup B protein-based active substance (MenPenta vaccine), suspension for injection, intramuscular use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Sanofi Pasteur, 14 Espace Henry Vallée, 69007 – Lyon, France.

EMA/PDCO/282096/2023
Amsterdam, 8 September 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-003379-PIP01-22

Scope of the application

Active substance(s): Neisseria Meningitidis Group A Polysaccharide Conjugated to Tetanus Toxoid Carrier Protein, Neisseria Meningitidis Group C Polysaccharide Conjugated to Tetanus Toxoid Carrier Protein, Neisseria Meningitidis Group W-135 Polysaccharide Conjugated to Tetanus Toxoid Carrier Protein, Neisseria Meningitidis Group Y Polysaccharide Conjugated to Tetanus Toxoid Carrier Protein, Recombinant Neisseria meningitidis serogroup B protein 1, Recombinant Neisseria meningitidis serogroup B protein 2, Recombinant Neisseria meningitidis serogroup B protein 3, Neisseria meningitidis serogroup B Protein-based active substance (MenPenta vaccine)

Invented name and authorisation status:

See Annex II

Condition(s):

Prevention of meningococcal disease (serogroups A, B, C, W and Y)

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Sanofi Pasteur

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sanofi Pasteur submitted for agreement to the European Medicines Agency on 16 December 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.



The procedure started on 30 January 2023.

Supplementary information was provided by the applicant on 30 May 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Prevention of meningococcal disease

The waiver applies to:

- the paediatric population from birth to less than 6 weeks of age;
- suspension for injection, intramuscular use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Prevention of meningococcal disease

2.1.1. Indication(s) targeted by the PIP

Active immunization of individuals from 6 weeks of age against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W and Y

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 weeks to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Suspension for injection.

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	Not applicable.
Clinical studies	Study 1 VAN00010 Dose finding study to evaluate safety and immunogenicity of MenPenta vaccine in children and adolescents from 10 years to less than 18 years of age (and adults). Study 2 VAN00011 Double-blind randomised trial to evaluate safety and immunogenicity of MenPenta vaccine compared to a licensed alternative administered concomitantly with routine vaccines in children and adolescents from 10 years to less than 18 years of age (and adults).

	<p>Study 3 VAN00013</p> <p>Open label active controlled trial to evaluate safety, immunogenicity and schedule finding of MenPenta vaccine in children from 6 weeks to less than 9 years of age.</p> <p>Study 4 VAN00014</p> <p>Double-blind randomised placebo-controlled trial to evaluate safety and immunogenicity of MenPenta vaccine compared to a licensed alternative administered concomitantly with routine paediatric vaccines to healthy children from 2 months to less than 24 months of age.</p> <p>Study 5 VAN00018</p> <p>Open-label follow-up trial of study VAN00010 (PIP study 1) to evaluate antibody persistence safety and immunogenicity of a booster dose of MenPenta vaccine in adolescents 3-4 years post-priming.</p>
Modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.